Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker.
Recent clinical studies implicate proteinuria as a key prognostic factor for renal and cardiovascular complications in hypertensives. The pathogenesis of proteinuria in hypertension is, however, poorly elucidated. Podocytes constitute the final filtration barrier in the glomerulus, and their dysfunction may play a pivotal role in proteinuria. In the present study, we examined the involvement of podocyte injury in Dahl salt-hypertensive rats, an animal model prone to hypertensive glomerulosclerosis, and explored the effects of inhibition of aldosterone. Four-week-old Dahl salt-resistant and salt-sensitive rats were fed a 0.3% or 8.0% NaCl diet. Some salt-loaded Dahl salt-sensitive rats were treated with a selective aldosterone blocker eplerenone (1.25 mg/g diet) or hydralazine (0.5 mmol/L). After 6 weeks, salt-loaded Dahl salt-sensitive rats developed severe hypertension, proteinuria, and glomerulosclerosis. Immunostaining for nephrin, a constituent of slit diaphragm, was attenuated, whereas expressions of damaged podocyte markers desmin and B7-1 were upregulated in the glomeruli of salt-loaded Dahl salt-sensitive rats. Electron microscopic analysis revealed podocyte foot process effacement. Podocytes were already impaired at as early as 2 weeks of salt loading in Dahl salt-sensitive rats, when proteinuria was modestly increased. Both eplerenone and hydralazine partially reduced systemic blood pressure as measured by indirect and direct methods in salt-loaded Dahl salt-sensitive rats, but only eplerenone dramatically improved podocyte damage and retarded the progression of proteinuria and glomerulosclerosis. Our findings suggest that podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and that inhibition of aldosterone by eplerenone is protective against podocyte damage, proteinuria, and glomerulosclerosis in this hypertensive model.
Nagase
Miki
M
Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo, Japan. mnagase-tky@umin.ac.jp
Shibata
Shigeru
S
Yoshida
Shigetaka
S
Nagase
Takashi
T
Gotoda
Takanari
T
Fujita
Toshiro
T
D000818:Animals; D017209:Apoptosis; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D000077545:Eplerenone; D005355:Fibrosis; D005923:Glomerulosclerosis, Focal Segmental / Q000209:etiology*; D006830:Hydralazine / Q000494:pharmacology; D006973:Hypertension / Q000150:complications* / Q000473:pathology* / Q000503:physiopathology / Q000652:urine; D007668:Kidney / Q000473:pathology; D008297:Male; D008854:Microscopy, Electron; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology*; D009393:Nephritis / Q000378:metabolism; D018384:Oxidative Stress; D050199:Podocytes / Q000187:drug effects / Q000473:pathology*; D011507:Proteinuria / Q000209:etiology / Q000503:physiopathology; D051381:Rats; D020303:Rats, Inbred Dahl; D013148:Spironolactone / Q000031:analogs & derivatives / Q000494:pharmacology; D013997:Time Factors
D015415:Biomarkers; D000451:Mineralocorticoid Receptor Antagonists; D006830:Hydralazine; D013148:Spironolactone; D000077545:Eplerenone